Results 11 to 20 of about 70,439 (302)

Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications [PDF]

Frontiers in Pharmacology
IntroductionWomen with Parkinson’s Disease (PD) have higher plasma exposure to levodopa and are particularly prone to developing complications during chronic levodopa therapy. However, there are no longitudinal studies focusing on differences in levodopa
Valeria Conti, Valeria Conti, Emanuela De Bellis, Graziamaria Corbi, Bruno Charlier, Bruno Charlier, Viviana Izzo, Viviana Izzo, Maria Claudia Russillo, Marianna Amboni, Marianna Amboni, Marina Picillo, Marina Picillo, Cesa Lorella Maria Scaglione, Ilaria Cani, Calogero Edoardo Cicero, Alessandra Nicoletti, Andrea Soricelli, Paolo Barone, Paolo Barone, Amelia Filippelli, Amelia Filippelli, Maria Teresa Pellecchia, Maria Teresa Pellecchia   +23 more
doaj   +2 more sources

Advancing the Treatment of Motor Fluctuations in Parkinson’s Disease with a Next-Generation Levodopa/Carbidopa Formulation [PDF]

Neurology and Therapy
As of today, levodopa remains the cornerstone of symptomatic management in Parkinson’s disease (PD). As PD progresses, the limitations of immediate-release (IR) levodopa/carbidopa, such as its short half-life and inconsistent absorption, result in ...
Fabrizio Stocchi, Mathias Knecht, Ivan Marjanovic, Achim Wach, Jaakko Kopra, Jaime Kulisevsky   +5 more
doaj   +2 more sources

Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan

Frontiers in Pediatrics, 2021
Introduction: Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5–1 mg/kg/day).
Kyoko Hoshino, Kyoko Hoshino, Kyoko Hoshino, Masaharu Hayashi, Masaharu Hayashi, Masaharu Hayashi, Asayo Ishizaki, Asayo Ishizaki, Kazue Kimura, Kazue Kimura, Masaya Kubota, Masaya Kubota, Atsuo Nezu, Atsuo Nezu, Akihiro Yasuhara, Akihiro Yasuhara   +15 more
doaj   +1 more source

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Frontiers in Neurology, 2022
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations ...
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi   +7 more
doaj   +1 more source

Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease

Clinical Parkinsonism & Related Disorders, 2023
Background: In people with Parkinson’s disease (PwPD), Freezing of Gait (FOG) episodes can be levodopa responsive (OFF-FOG) or levodopa unresponsive (ONOFF-FOG).
Tuhin Virmani, Lakshmi Pillai, Aliyah Glover, Reid D. Landes   +3 more
doaj   +1 more source

Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.

PLoS ONE, 2020
A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication.
Jin Yong Hong, Mun Kyung Sunwoo, Jung Han Yoon, Suk Yun Kang, Young H Sohn, Phil Hyu Lee, Seo Hyun Kim   +6 more
doaj   +1 more source

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis

Journal of Parkinson’s Disease, 2021
Background: The widely divergent responsiveness of Parkinson’s disease (PD) patients to levodopa is an important clinical issue because of its relationship with quality of life and disease prognosis.
Cheng Zhou, Tao Guo, JingJing Wu, Linbo Wang, Xueqin Bai, Ting Gao, Xiaojun Guan, Luyan Gu, Peiyu Huang, Min Xuan, Quanquan Gu, Xiaojun Xu, Baorong Zhang, Wei Cheng, Jianfeng Feng, Minming Zhang   +15 more
doaj   +1 more source

Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes

Cells, 2021
Dyskinesias are characterized by abnormal repetitive involuntary movements due to dysfunctional neuronal activity. Although levodopa-induced dyskinesia, characterized by tic-like abnormal involuntary movements, has no clinical treatment for Parkinson’s ...
Luca Pagliaroli, Abel Fothi, Ester Nespoli, Istvan Liko, Borbala Veto, Piroska Devay, Flora Szeri, Bastian Hengerer, Csaba Barta, Tamas Aranyi   +9 more
doaj   +1 more source

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics

Current Therapeutic Research, 2020
: Background: Parkinson's disease is a neurodegenerative disorder, and a major cause of disability. Levodopa, a prodrug of dopamine, remains the gold standard in the pharmacological management of Parkinson's disease.
Benedicta Obenewaa Dankyi, MPhil, Seth Kwabena Amponsah, PhD, Grace Lovia Allotey-Babington, PhD, Ismaila Adams, BPharm, Nana Aboadwe Goode, BPharm, Henry Nettey, PharmD/PhD   +5 more
doaj   +1 more source

Sonolysis of levodopa and paracetamol in aqueous solutions. [PDF]

, 2009
Pharmaceutical products are often present in wastewater treatment effluents, rivers, lakes and, more rarely, in groundwater. The advanced oxidation methods, like ultrasound, find a promising future in the area of wastewater treatment.
Delmas, Henri, Julcour-Lebigue, Carine, Jáuregui Haza, Ulises Javier, Quesada-Peñate, Isariebel, Wilhelm, Anne-Marie   +4 more
core   +1 more source